Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Digitising healthcare

by Peter Ruffley

- PMLiVE

Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib

Investigational drug beat Pfizer's Bosulif in phase 3 study

- PMLiVE

bluebird bio’s beta thalassaemia gene therapy Zynteglo scores promising long-term data

Results presented at annual American Society of Haematology (ASH) meeting

- PMLiVE

The Lancet confirms effectiveness of AZ/Oxford University’s COVID-19 vaccine

Final average efficacy analysis found to be 70.4%

Lucid Group Evolve and Simplify its Brand Architecture

The current pandemic has forced many industries to find new ways of working. Within medical communications (medcomms), this has involved pivoting quickly towards a digital-first approach in order to optimise...

Lucid Group Communications Limited

University spin-out fund makes half a million pound first investments

University partnership Northern Accelerator has made over £500,000 worth of investments into two innovative university spin-out businesses in the health and biotech sectors from its £1.7M Seed Investment Fund

Onyx Health

- PMLiVE

Accord Healthcare’s COVID-19 agility praised at PMEA 2020

Accord Healthcare picks up inaugural Agility Award in Pharma Market Excellence

- PMLiVE

Q&A: Sarah Mikhailov

PME interviews Havas Life Medicom's Managing Partner

- PMLiVE

Why digital is the solution to the healthcare crisis

Amid the uncertainty of the pandemic, rather than halting progress, in many ways the crisis has expedited it

- PMLiVE

Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial

Drug combination failed to improve overall survival rate

11 London - Migraine-friendly colours

Migraine-friendly colours for the home

You may not realise it, but colour impacts migraines. 11 London worked with Teva Pharmaceuticals UK, Dulux Paints and the National Migraine Centre to test this theory among 1,200 migraine...

11 London

- PMLiVE

How can virtual pharma companies de-risk new product launches?

The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links